PHARMACOKINETICS AND PHARMACODYNAMICS OF AMLODIPINE

被引:59
|
作者
ABERNETHY, DR [1 ]
机构
[1] BROWN UNIV,ROGER WILLIAMS GEN HOSP,DEPT MED,DIV CLIN PHARMACOL,PROVIDENCE,RI 02908
关键词
PHARMACOKINETICS; PHARMACODYNAMICS; AMLODIPINE;
D O I
10.1159/000175050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Amlodipine is a low-clearance, dihydropyridine calcium antagonist. The slow rate of elimination (elimination half-life of 40-60 h) confers several pharmacokinetic characteristics that are not seen with other calcium-antagonist drugs. It has high oral bioavailability (60-80%) and accumulates to a steady-state with once-daily administration over a period of 1-1 1/2 weeks. Fluctuation of plasma drug concentration between doses is between 20 and 2 5 % when once-daily dosing is used. Onset of effect is gradual after oral administration which is due, in part, to an intermediate rate of drug absorption (peak plasma drug concentration occurs 6-8 h after dosing) and perhaps also to the physicochemical characteristics of the drug-cell membrane-receptor interaction. The pharmacodynamic profile of the drug in hypertensive patients is consistent with the disposition of the drug. After single doses, blood pressure decreases gradually over 4-8 h and may slowly return to baseline over 24-72 h. No change in heart rate is noted after the dose as the onset is gradual and physiological reflexes are not activated. During chronic, oral, once-daily dosing blood pressure is decreased from pretreatment baseline with little fluctuation over the 24-hour dose interval. Discontinuation of amlodipine treatment results in a slow return of blood pressure to baseline over 7-10 days, with no evidence of a 'rebound' effect. Amlodipine is a low-clearance. dihydropyridine calcium antagonist which is effective for the treatment of hypertension and angina pectoris with once-daily dosing.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 50 条
  • [21] Gender differences in pharmacokinetics and pharmacodynamics
    Beierle, I
    Meibohm, B
    Derendorf, H
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1999, 37 (11) : 529 - 547
  • [22] The pharmacodynamics and pharmacokinetics of mivacurium in children
    Ostergaard, D
    Gätke, MR
    Berg, H
    Rasmussen, SN
    Viby-Mogensen, J
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2002, 46 (05) : 512 - 518
  • [23] Volterra series in pharmacokinetics and pharmacodynamics
    Verotta, D
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2003, 30 (05) : 337 - 362
  • [24] Pharmacokinetics and Pharmacodynamics of Morroniside: A Review
    Li, Bo
    Lei, Shanshan
    Xiong, Shan
    Chen, Suhong
    Zhang, Zhenqing
    NATURAL PRODUCT COMMUNICATIONS, 2019, 14 (06)
  • [25] Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem
    Conte, JE
    Golden, JA
    Kelley, MG
    Zurlinden, E
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 (06) : 449 - 456
  • [26] Pharmacokinetics and pharmacodynamics of inhaled corticosteroids
    Derendorf, H
    Hochhaus, G
    Meibohm, B
    Möllmann, H
    Barth, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (04) : S440 - S446
  • [27] Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
    Elhence, Hirsh
    Mongkolrattanothai, Kanokporn
    Mohandas, Sindhu
    Neely, Michael N.
    PHARMACEUTICS, 2023, 15 (01)
  • [28] Pharmacokinetics and pharmacodynamics of antimicrobial drugs
    Czock, David
    Markert, Christoph
    Hartman, Bertram
    Keller, Frieder
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (05) : 475 - 487
  • [29] Pharmacokinetics and pharmacodynamics of drugs for sedation
    Lee, Yoon Sook
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2013, 56 (04): : 279 - 284
  • [30] Pharmacokinetics and pharmacodynamics of ketoprofen plasters
    Heo, Sung-Koun
    Cho, Jeiwon
    Cheon, Ji-Woong
    Choi, Min-Koo
    Im, Dong-Soon
    Kim, Jung Ju
    Choi, Yang Gyu
    Jeon, Do Yong
    Chung, Suk-Jae
    Shim, Chang-Koo
    Kim, Dae-Duk
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2008, 29 (01) : 37 - 44